Yrondi, Antoine
Blanc, Olivier
Anguill, Loic
Arbus, Christophe
Boudieu, Ludivine
Patoz, Marie-Camille
Arnould, Adeline
Charpeaud, Thomas
Genty, Jean-Baptiste
Abidine, Racan
Redon, Maximilien
Rey, Romain
Aouizerate, Bruno
Bennabi, Djamila
El-Hage, Wissam
Etain, Bruno
Holtzmann, Jérôme
Leboyer, Marion
Molière, Fanny
Richieri, Raphaelle Marie
Stéphan, Florian
Vaiva, Guillaume
Sauvaget, Anne
Poulet, Emmanuel
Haffen, Emmanuel
Courtet, Philippe
Fossati, Philippe
Llorca, Pierre-Michel
Samalin, Ludovic
Article History
Received: 5 January 2024
Accepted: 25 June 2024
First Online: 3 July 2024
Declarations
:
: The assessment protocol was approved by the relevant ethical review board (CPP Sud-Est VI, 2016 / CE 07). This a retrospective study. All data were collected anonymously.All patients who were hospitalized, are informed and consent that their data could be used retrospectively for research.
: All patients who were hospitalized, are informed and consent that their data could be used retrospectively for research.
: Pr. Samalin has received personal fees and/or non-financial support from Janssen, Lundbeck and Otsuka.Pr Yrondi has received speaker's honoraria (AstraZeneca, Janssen, Lundbeck, Otsuka, Servier), carried out clinical studies in relation to the.development of a medicine (Janssen) unrelated to this work.Dr Genty has received speaker's honoraria from Servier.Pr Sauvaget has received personal fees and/or non-financial support from Janssen, and Lundbeck.Pr Poulet has received personal fees and/or non-financial support from Janssen, EISAI, Otsuka and Lundbeck.Dr Holtzmann has received personal fees and/or non-financial support from Janssen and Lundbeck.Pr Richieri has received speaker's honoraria from Otsuka and Janssen-Cilag. She has served on advisory boards for LivaNova.Pr El-Hage has received speaker's honoraria from CHUGAI, EISAI, Lundbeck, Janssen-Cilag, and UCB unrelated to this work. He served on advisory boards for Janssen-Cilag and Lundbeck.Pr Aouizerate has received speaker's honoraria from Lundbeck,Lilly, and Janssen-Cilag. He has served on advisory boards for Janssen-Cilag.Pr Haffen acted in advisory capacities, carried out clinical studies inrelation to the development of a medicine, received personal researches,studies or travel allowance, gave presentations at meetings, and received remuneration for input from the following pharmaceutical organisations: AstraZeneca, BMS, Cellgene, Euthérapie—Servier, Janssen, Elli Lilly, Lundbeck, LivaNova, Otsuka, Pfizer, Sanofi.Pr Llorca has received grants, honoraria, or consulting fees fromESAI, Gedeon Richeter, Janssen, Lundbeck, Otsuka and Sanofi.No potential conflict of interest was reported by the other authors.